In a 2026 survey, 48 percent of life sciences executives stated that new drug and device launches were the leading biopharma growth strategy in the United States. About 40 percent reported that investing in an AI-enabled platform would be a key biopharma growth strategy.
Profit from the additional features of your individual account
Currently, you are using a shared account. To use individual functions (e.g., mark statistics as favourites, set
statistic alerts) please log in with your personal account.
If you are an admin, please authenticate by logging in again.
Learn more about how ÌÇÐÄÆƽâ°æ can support your business.
Deloitte. (December 9, 2025). Leading biopharma growth strategies for life sciences executives in the U.S. from August to September 2026 [Graph]. In ÌÇÐÄÆƽâ°æ. Retrieved August 06, 2026, from /statistics/1664050/biopharma-growth-strategies-us/
Deloitte. "Leading biopharma growth strategies for life sciences executives in the U.S. from August to September 2026." Chart. December 9, 2025. ÌÇÐÄÆƽâ°æ. Accessed August 06, 2026. /statistics/1664050/biopharma-growth-strategies-us/
Deloitte. (2025). Leading biopharma growth strategies for life sciences executives in the U.S. from August to September 2026. ÌÇÐÄÆƽâ°æ. ÌÇÐÄÆƽâ°æ Inc.. Accessed: August 06, 2026. /statistics/1664050/biopharma-growth-strategies-us/
Deloitte. "Leading Biopharma Growth Strategies for Life Sciences Executives in The U.S. from August to September 2026." ÌÇÐÄÆƽâ°æ, ÌÇÐÄÆƽâ°æ Inc., 9 Dec 2025, /statistics/1664050/biopharma-growth-strategies-us/
Deloitte, Leading biopharma growth strategies for life sciences executives in the U.S. from August to September 2026 ÌÇÐÄÆƽâ°æ, /statistics/1664050/biopharma-growth-strategies-us/ (last visited August 06, 2026)
Leading biopharma growth strategies for life sciences executives in the U.S. from August to September 2026 [Graph], Deloitte, December 9, 2025. [Online]. Available: /statistics/1664050/biopharma-growth-strategies-us/
